Maravai LifeSciences - MRVI Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $11.44
  • Forecasted Upside: 58.07%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.23 (3.28%)

This chart shows the closing price for MRVI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Maravai LifeSciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRVI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRVI

Analyst Price Target is $11.44
▲ +58.07% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Maravai LifeSciences in the last 3 months. The average price target is $11.44, with a high forecast of $17.00 and a low forecast of $7.00. The average price target represents a 58.07% upside from the last price of $7.24.

This chart shows the closing price for MRVI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 10 contributing investment analysts is to moderate buy stock in Maravai LifeSciences. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$8.00 ➝ $10.00Low
4/10/2024Craig HallumInitiated CoverageBuy$15.00Low
2/23/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$12.00 ➝ $14.00Low
2/23/2024Stifel NicolausLower TargetBuy ➝ Buy$11.00 ➝ $10.00Low
12/12/2023Bank of AmericaUpgradeNeutral ➝ Buy$10.00 ➝ $8.00Low
11/9/2023The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$8.00 ➝ $7.00Low
11/9/2023Morgan StanleyLower TargetOverweight ➝ Overweight$12.00 ➝ $11.00Low
8/9/2023Morgan StanleyLower TargetOverweight ➝ Overweight$27.00 ➝ $12.00Low
8/8/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$20.00 ➝ $18.00Low
8/8/2023Deutsche Bank AktiengesellschaftLower TargetBuy ➝ Buy$23.00 ➝ $17.00Low
8/8/2023The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$12.00 ➝ $8.00Low
8/8/2023Stifel NicolausLower Target$17.00 ➝ $12.00Low
8/8/2023Bank of AmericaLower Target$15.00 ➝ $12.00Low
8/8/2023Credit Suisse GroupLower TargetNeutral ➝ Neutral$14.00 ➝ $11.00Low
8/8/2023Robert W. BairdLower TargetOutperform ➝ Outperform$18.00 ➝ $11.00Low
8/8/2023KeyCorpDowngradeOverweight ➝ Sector WeightLow
5/23/202358.comReiterated RatingDowngradeLow
5/23/2023Credit Suisse GroupDowngradeOutperform ➝ Neutral$18.00 ➝ $14.00Low
5/9/2023Deutsche Bank AktiengesellschaftLower Target$25.00 ➝ $23.00Low
5/9/2023The Goldman Sachs GroupDowngradeBuy ➝ NeutralLow
5/9/2023Stifel NicolausLower Target$18.00 ➝ $17.00Low
5/9/2023Royal Bank of CanadaLower Target$22.00 ➝ $20.00Low
5/9/2023Credit Suisse GroupLower Target$23.00 ➝ $18.00Low
2/24/2023Morgan StanleyLower TargetOverweight$32.00 ➝ $29.00Low
2/23/2023Credit Suisse GroupLower TargetOutperform$26.00 ➝ $23.00Low
2/23/2023KeyCorpLower TargetOverweight$28.00 ➝ $24.00Low
2/23/2023Robert W. BairdLower TargetOutperform$25.00 ➝ $22.00Low
1/17/2023The Goldman Sachs GroupLower TargetBuy$18.00 ➝ $16.00Low
1/5/2023UBS GroupDowngradeBuy ➝ Neutral$20.00 ➝ $16.00Low
12/13/2022Deutsche Bank AktiengesellschaftInitiated CoverageBuy$25.00Low
12/6/2022Royal Bank of CanadaInitiated CoverageOutperform$22.00Low
11/4/2022The Goldman Sachs GroupLower TargetBuy$30.00 ➝ $18.00Low
11/4/2022Morgan StanleyLower TargetOverweight$35.00 ➝ $32.00Low
11/3/2022Credit Suisse GroupLower TargetOutperform$34.00 ➝ $26.00Low
11/3/2022Robert W. BairdLower Target$34.00 ➝ $25.00Low
11/3/2022Bank of AmericaDowngradeBuy ➝ Neutral$32.00 ➝ $17.00Low
11/3/2022KeyCorpLower TargetOverweight$35.00 ➝ $28.00Low
8/24/2022Credit Suisse GroupInitiated CoverageOutperform$34.00Low
8/8/2022Morgan StanleyLower TargetOverweight$49.00 ➝ $35.00Low
8/5/2022Robert W. BairdLower Target$40.00 ➝ $34.00Low
7/14/2022The Goldman Sachs GroupLower TargetBuy$44.00 ➝ $35.00Low
5/6/2022Robert W. BairdLower Target$48.00 ➝ $40.00High
2/25/2022Morgan StanleyLower TargetOverweight$59.00 ➝ $54.00High
2/24/2022Robert W. BairdLower Target$60.00 ➝ $48.00Medium
8/12/2021Morgan StanleyBoost TargetOverweight$54.00 ➝ $62.00High
8/11/2021Credit Suisse GroupBoost TargetOutperform$44.00 ➝ $54.00High
8/11/2021KeyCorpBoost TargetOverweight$46.00 ➝ $58.00High
8/11/2021Robert W. BairdBoost TargetOutperform$51.00 ➝ $59.00High
8/5/2021Credit Suisse GroupInitiated CoverageOutperform$44.00Low
5/11/2021Credit Suisse GroupBoost TargetOutperform$42.00 ➝ $44.00Low
3/8/2021Credit Suisse GroupBoost TargetOutperform$34.00 ➝ $42.00N/A
3/3/2021Morgan StanleyBoost TargetOverweight$35.00 ➝ $54.00High
3/3/2021KeyCorpBoost TargetOverweight$39.00 ➝ $46.00High
3/1/2021Credit Suisse GroupBoost TargetOutperform$31.00 ➝ $34.00Low
2/10/2021KeyCorpBoost TargetOverweight$33.00 ➝ $39.00Low
12/16/2020KeyCorpInitiated CoverageOverweight$33.00N/A
12/15/2020Morgan StanleyInitiated CoverageOverweight$35.00Low
12/15/2020Stifel NicolausInitiated CoverageBuy$31.00Medium
12/15/2020William BlairInitiated CoverageOutperformMedium
12/15/2020Credit Suisse GroupInitiated CoverageOutperformMedium
12/15/2020The Goldman Sachs GroupInitiated CoverageBuy$38.00Medium
12/15/2020Bank of AmericaInitiated CoverageBuy$31.00Medium
12/15/2020Jefferies Financial GroupInitiated CoverageBuyMedium
12/15/2020Robert W. BairdInitiated CoverageOutperform$31.00Medium
12/14/2020UBS GroupInitiated CoverageBuy$32.00Low
(Data available from 6/23/2019 forward)

News Sentiment Rating

1.08 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 11 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
  • 8 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 9 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 8 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 8 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Maravai LifeSciences logo
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $7.24
Low: $7.08
High: $7.37

50 Day Range

MA: $8.85
Low: $6.89
High: $11.34

52 Week Range

Now: $7.24
Low: $4.52
High: $13.60


2,330,636 shs

Average Volume

1,694,827 shs

Market Capitalization

$1.82 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Maravai LifeSciences?

The following sell-side analysts have issued reports on Maravai LifeSciences in the last year: Bank of America Co., Craig Hallum, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, KeyCorp, Morgan Stanley, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for MRVI.

What is the current price target for Maravai LifeSciences?

9 Wall Street analysts have set twelve-month price targets for Maravai LifeSciences in the last year. Their average twelve-month price target is $11.44, suggesting a possible upside of 58.1%. Deutsche Bank Aktiengesellschaft has the highest price target set, predicting MRVI will reach $17.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $7.00 for Maravai LifeSciences in the next year.
View the latest price targets for MRVI.

What is the current consensus analyst rating for Maravai LifeSciences?

Maravai LifeSciences currently has 3 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for MRVI.

What other companies compete with Maravai LifeSciences?

How do I contact Maravai LifeSciences' investor relations team?

Maravai LifeSciences' physical mailing address is 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA, 92121. The company's listed phone number is 858-546-0004 and its investor relations email address is [email protected]. The official website for Maravai LifeSciences is Learn More about contacing Maravai LifeSciences investor relations.